Skip to content
HowShorted

BRAINSTORM CELL THERAPEUTICS INC. short interest in 2022

In 2022, BRAINSTORM CELL THERAPEUTICS INC.'s disclosed short interest ran from 3.13% of shares outstanding on 14 Jan 2022 to 5.61% on 30 Dec 2022, a change of +2.48 percentage points. The year's high was 7.37% on 31 Oct 2022 and its low 1.55% on 15 Aug 2022, averaging 3.31% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 16.16 days on 15 Dec 2022. Full history: BRAINSTORM CELL THERAPEUTICS INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for BRAINSTORM CELL THERAPEUTICS INC. in 2022

2022 in figures

Start of year
3.13% (14 Jan 2022)
End of year
5.61% (30 Dec 2022)
Change
+2.48 pp
High
7.37% (31 Oct 2022)
Low
1.55% (15 Aug 2022)
Average
3.31%
Highest days to cover
16.16 (15 Dec 2022)
SEC filings marked
9

Every report in 2022

BRAINSTORM CELL THERAPEUTICS INC. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20223.13%9.49
31 Jan 20222.81%7.06results (8-K)
15 Feb 20222.18%11.81
28 Feb 20222.03%10.58
15 Mar 20222.02%13.90
31 Mar 20221.83%11.6410-K filed, results (8-K)
14 Apr 20221.68%8.82
29 Apr 20221.65%13.61
13 May 20221.75%5.56
31 May 20221.85%13.2110-Q filed, results (8-K)
15 Jun 20221.76%13.59
30 Jun 20221.76%10.83
15 Jul 20221.59%10.50
29 Jul 20221.64%12.71
15 Aug 20221.55%2.1610-Q filed, results (8-K)
31 Aug 20222.12%3.00
15 Sep 20223.55%5.32
30 Sep 20225.43%7.14
14 Oct 20226.68%10.06
31 Oct 20227.37%15.96
15 Nov 20227.07%6.0310-Q filed, results (8-K)
30 Nov 20226.19%10.11
15 Dec 20226.19%16.16
30 Dec 20225.61%10.40

See also: BRAINSTORM CELL THERAPEUTICS INC.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.